

# Isidoro MartÃ-nez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7157227/publications.pdf>

Version: 2024-02-01

53  
papers

1,704  
citations

361296

20  
h-index

289141

40  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2429  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antibody levels to <sc>SARS-CoV-2</sc> spike protein in mothers and children from delivery to six months later. Birth, 2023, 50, 418-427.	1.1	5
2	Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. Journal of Internal Medicine, 2022, 291, 232-240.	2.7	21
3	Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19. Journal of Infection, 2022, 84, 418-467.	1.7	7
4	Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients. Biomedicine and Pharmacotherapy, 2022, 147, 112623.	2.5	6
5	Early innate immune response triggered by the human respiratory syncytial virus and its regulation by ubiquitination/deubiquitination processes. Journal of Biomedical Science, 2022, 29, 11.	2.6	6
6	Misdiagnosis rate among negative COVID-19 patients in real-life with Panbio COVID-19 antigen rapid test during 2021. Journal of Infection, 2022, , .	1.7	0
7	Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis. Biomedicine and Pharmacotherapy, 2022, 150, 113024.	2.5	1
8	Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis. Drugs, 2021, 81, 419-443.	4.9	12
9	TRPM5 rs886277 Polymorphism Predicts Hepatic Fibrosis Progression in Non-Cirrhotic HCV-Infected Patients. Journal of Clinical Medicine, 2021, 10, 483.	1.0	1
10	The Challenging Road to Hepatitis C Virus Eradication. Journal of Clinical Medicine, 2021, 10, 611.	1.0	5
11	HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. Journal of Biomedical Science, 2021, 28, 23.	2.6	6
12	Role of G2-S16 Polyanionic Carbosilane Dendrimer in the Prevention of Respiratory Syncytial Virus Infection In Vitro and In Vivo in Mice. Polymers, 2021, 13, 2141.	2.0	2
13	HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Frontiers in Immunology, 2021, 12, 723196.	2.2	14
14	Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain. International Journal of Drug Policy, 2021, 96, 103424.	1.6	10
15	Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case-control study. Aids, 2020, 34, 1891-1897.	1.0	4
16	Metabolic changes during respiratory syncytial virus infection of epithelial cells. PLoS ONE, 2020, 15, e0230844.	1.1	35
17	Hepatitis C virus vaccine design: focus on the humoral immune response. Journal of Biomedical Science, 2020, 27, 78.	2.6	23
18	Innate Immune Response against Hepatitis C Virus: Targets for Vaccine Adjuvants. Vaccines, 2020, 8, 313.	2.1	12

#	ARTICLE	IF	CITATIONS
19	Downregulation of A20 Expression Increases the Immune Response and Apoptosis and Reduces Virus Production in Cells Infected by the Human Respiratory Syncytial Virus. <i>Vaccines</i> , 2020, 8, 100.	2.1	11
20	Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR. <i>Scientific Reports</i> , 2019, 9, 12163.	1.6	2
21	siRNA-Mediated Simultaneous Regulation of the Cellular Innate Immune Response and Human Respiratory Syncytial Virus Replication. <i>Biomolecules</i> , 2019, 9, 165.	1.8	5
22	TNFAIP3, TNIP1, and MyD88 Polymorphisms Predict Septic-Shock-Related Death in Patients Who Underwent Major Surgery. <i>Journal of Clinical Medicine</i> , 2019, 8, 283.	1.0	5
23	Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. <i>Biomolecules</i> , 2019, 9, 143.	1.8	7
24	Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study. <i>Infection, Genetics and Evolution</i> , 2019, 67, 112-120.	1.0	2
25	Chimeric <i>Pneumoviridae</i> fusion proteins as immunogens to induce cross-neutralizing antibody responses. <i>EMBO Molecular Medicine</i> , 2018, 10, 175-187.	3.3	10
26	Vitamin D in Human Immunodeficiency Virus Infection: Influence on Immunity and Disease. <i>Frontiers in Immunology</i> , 2018, 9, 458.	2.2	110
27	A Two-Dimensional Human Minilung System (Model) for Respiratory Syncytial Virus Infections. <i>Viruses</i> , 2017, 9, 379.	1.5	8
28	TRIM25 in the Regulation of the Antiviral Innate Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 1187.	2.2	109
29	Apoptosis, Toll-like, RIG-I-like and NOD-like Receptors Are Pathways Jointly Induced by Diverse Respiratory Bacterial and Viral Pathogens. <i>Frontiers in Microbiology</i> , 2017, 8, 276.	1.5	22
30	Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. <i>Journal of Translational Medicine</i> , 2016, 14, 257.	1.8	20
31	Induction of DNA double-strand breaks and cellular senescence by human respiratory syncytial virus. <i>Virulence</i> , 2016, 7, 427-442.	1.8	49
32	ISG15 Is Upregulated in Respiratory Syncytial Virus Infection and Reduces Virus Growth through Protein ISGylation. <i>Journal of Virology</i> , 2016, 90, 3428-3438.	1.5	56
33	Urokinase receptor-deficient mice mount an innate immune response to and clarify respiratory viruses as efficiently as wild-type mice. <i>Virulence</i> , 2015, 6, 710-715.	1.8	5
34	Roflumilast Inhibits Respiratory Syncytial Virus Infection in Human Differentiated Bronchial Epithelial Cells. <i>PLoS ONE</i> , 2013, 8, e69670.	1.1	32
35	Respiratory Syncytial Virus Inhibits Ciliogenesis in Differentiated Normal Human Bronchial Epithelial Cells: Effectiveness of N-Acetylcysteine. <i>PLoS ONE</i> , 2012, 7, e48037.	1.1	62
36	Reduced innate immune response, apoptosis, and virus release in cells cured of respiratory syncytial virus persistent infection. <i>Virology</i> , 2011, 410, 56-63.	1.1	7

#	ARTICLE	IF	CITATIONS
37	Cultures of HEp-2 cells persistently infected by human respiratory syncytial virus differ in chemokine expression and resistance to apoptosis as compared to lytic infections of the same cell type. <i>Virology</i> , 2009, 388, 31-41.	1.1	26
38	Distinct gene subsets are induced at different time points after human respiratory syncytial virus infection of A549 cells. <i>Journal of General Virology</i> , 2007, 88, 570-581.	1.3	63
39	Biological Differences between Vesicular Stomatitis Virus Indiana and New Jersey Serotype Glycoproteins: Identification of Amino Acid Residues Modulating pH-Dependent Infectivity. <i>Journal of Virology</i> , 2005, 79, 3578-3585.	1.5	20
40	Recombinant vesicular stomatitis (Indiana) virus expressing New Jersey and Indiana glycoproteins induces neutralizing antibodies to each serotype in swine, a natural host. <i>Vaccine</i> , 2004, 22, 4035-4043.	1.7	12
41	Vesicular Stomatitis Virus Glycoprotein Is a Determinant of Pathogenesis in Swine, a Natural Host. <i>Journal of Virology</i> , 2003, 77, 8039-8047.	1.5	50
42	A model for the generation of multiple A to G transitions in the human respiratory syncytial virus genome: predicted RNA secondary structures as substrates for adenosine deaminases that act on RNA. <i>Journal of General Virology</i> , 2002, 83, 1445-1455.	1.3	37
43	Reduced expression of surface glycoproteins in mouse fibroblasts persistently infected with human respiratory syncytial virus (HRSV). <i>Archives of Virology</i> , 2001, 146, 669-683.	0.9	6
44	Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. <i>Journal of General Virology</i> , 2000, 81, 2715-2722.	1.3	91
45	Evolutionary pattern of the G glycoprotein of human respiratory syncytial viruses from antigenic group B: the use of alternative termination codons and lineage diversification.. <i>Journal of General Virology</i> , 1999, 80, 125-130.	1.3	61
46	Enhanced neutralization of human respiratory syncytial virus by mixtures of monoclonal antibodies to the attachment (G) glycoprotein.. <i>Journal of General Virology</i> , 1998, 79, 2215-2220.	1.3	40
47	Unusual Antigenic and Genetic Characteristics of Human Respiratory Syncytial Viruses Isolated in Cuba. <i>Journal of Virology</i> , 1998, 72, 7589-7592.	1.5	16
48	Antigenic structure, evolution and immunobiology of human respiratory syncytial virus attachment (G) protein.. <i>Journal of General Virology</i> , 1997, 78, 2411-2418.	1.3	188
49	Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants.. <i>Journal of General Virology</i> , 1997, 78, 2419-2429.	1.3	130
50	Host Cell Effect upon Glycosylation and Antigenicity of Human Respiratory Syncytial Virus G Glycoprotein. <i>Virology</i> , 1996, 221, 301-309.	1.1	66
51	Evolutionary pattern of human respiratory syncytial virus (subgroup A): cocirculating lineages and correlation of genetic and antigenic changes in the G glycoprotein. <i>Journal of Virology</i> , 1994, 68, 5448-5459.	1.5	190
52	Mapping of Monoclonal Antibody Epitopes of the Human Respiratory Syncytial Virus P Protein. <i>Virology</i> , 1993, 195, 239-242.	1.1	14
53	Hepatitis E Virus Seroprevalence is Associated with Neurodegenerative Disorders in Older People with Dementia: A Case-Control Study. <i>Journal of Infectious Diseases</i> , 0, , .	1.9	2